NeoPharm 
Welcome,         Profile    Billing    Logout  
 5 Products   63 Diseases  5 Products   156 Trials   7159 News 
183 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Removab (catumaxomab) / NeoPharm, Trion Pharma
ChiCTR1900028626: A two-stage, multi-center, open-label, randomized, controlled trial for comparing the efficacy and safety of intra-peritoneal infusion of catumaxomab and treatment of investigator choice in patients with advanced gastric carcinoma with peritoneal metastasis

Recruiting
3
282
 
catumaxomab ;The treatment of investigator choice
Beijing Cancer Hospital; Guangzhou LintonPharm Co., Ltd., Guangzhou LintonPharm Co.,Ltd.
Gastric carcinoma
 
 
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Recruiting
3
282
RoW
Catumaxomab, The treatment of investigator choice
LintonPharm Co.,Ltd.
Stomach Neoplasms
03/23
08/23
2010-022810-26: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA

Ongoing
2
40
Europe
Removab, Removab (Catumaxomab), Removab (Catumaxomab)
University Witten/Herdecke
PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA
 
 
ChiCTR2100044274: A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who Have Failed or are Intolerant to Bacillus Calmette-Guerin (BCG) Vaccine

Recruiting
1/2
161
 
intravesical catumaxomab
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Guangzhou LintonPharm Co., Ltd., Guangzhou LintonPharm Co.,Ltd.
Bladder Cancer
 
 
NCT04799847: Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Recruiting
1/2
161
RoW
Catumaxomab
LintonPharm Co.,Ltd.
Bladder Cancer
11/24
11/24
CATUNIBLA, NCT04819399: Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Recruiting
1
30
Europe
Catumaxomab
Lindis Biotech GmbH
Urinary Bladder Neoplasms
12/22
12/23
Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
2021-003089-11: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico (TRAINING)

Not yet recruiting
4
80
Europe
Grafalon, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona, Tacrolimus, Concentrate for solution for infusion, Capsule, Grafalon. Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit. Intravenous Use. Neovii Biotech Gmbh, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona
Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Instituto de Salud Carlos III
Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with Grafalon decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT. La inflamación subclínica, es muy frecuente tras el trasplante renal (TX), aún en los pacientes de bajo riesgo inmunológico, y puede evolucionar a lesiones crónicas tipo fibrosis intersticial/ atrofia tubular (FIAT) y deterioro de la función renal. El objetivo es determinar si el tratamiento precoz de las lesiones borderline (3 m post-TX) con Grafalon disminuye la progresión de FIAT y deterioro de la función renal comparado con la terapia convencional después de dos años de seguimiento post-TX., The aim of the clinical trial is to study whether treatment of subclinical graft inflammation with grafalon improves kidney function and graft survival. El objetivo del ensayo clínico es estudiar si el tratamiento de la inflamación subclínica del injerto con grafalon mejora la función renal y la supervivencia del injerto., Not possible to specify
 
 
NCT03789006: Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Recruiting
4
300
RoW
Antithymocyte Immunoglobulin (Rabbit), grafalon, Interleukin 2 Receptor Antagonist, Basiliximab
University of Khartoum, National Center for Kidney Diseases and Surgery
Kidney Transplant Rejection
03/22
03/24
NCT04936282: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Recruiting
4
80
Europe
Grafalon, Normal Treatment
Fundación Canaria de Investigación Sanitaria
Kidney Transplant Failure and Rejection
06/24
06/24
2021-003282-36: Studying Conditioning Regimen In Pediatric Transplantation – AML

Ongoing
3
230
Europe
Cyclophosphamide, Melphalan, Fludarabine, Clofarabine, Concentrate for dispersion for infusion, Powder for solution for infusion, Powder for dispersion for infusion, Busilvex, Grafalon, Thymoglobuline
Västra Götalands Regionen, Funding application submitted.
Acute myeloid leukemia (AML) in children, AML is a type of blood cancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2008-000101-11: Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population with haematologic malignancies riceiving non allogenic stem cell transplantation.

Ongoing
3
160
Europe
ATG-Fresenius, ATG-Fresenius
OSPEDALE POLICLINICO S. MATTEO
graft versus host disease profilactic use
 
 
2021-000853-17: Randomized comparison of Cyclophosphamide and ATG for prophylaxis of GvHD after unrelated donor transplantation Randomisierter Vergleich von Cyclophosphamid und ATG zur Vorbeugung von GvHD nach unverwandter Blutstammzelltransplantation

Not yet recruiting
3
540
Europe
Powder for solution for injection/infusion, Concentrate for solution for infusion, Grafalon 20 mg/ml
DKMS Group gGmbH, DKMS Group gGmbH
AML, t-MN, MDS, MDS/MPN, CMML-1/CMML-2, AML, t-MN, MDS, MDS/MPN, CMML-1/CMML-2, Diseases [C] - Cancer [C04]
 
 
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Recruiting
3
540
Europe
Cyclophosphamide, all brands, ATG, ATG Grafalon
DKMS gemeinnützige GmbH
Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML
08/25
08/26
OPTISAGE, NCT06083129: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Not yet recruiting
3
324
NA
Grafalon, Thymoglobulin
Assistance Publique - Hôpitaux de Paris
GVHD
02/27
11/28
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
FORUM, NCT01949129 / 2012-003032-22: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting
2/3
1800
Europe, Canada, RoW
VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin
St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group
Acute Lymphoblastic Leukaemia
06/25
04/30
ACTRN12619000623190: An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.

Recruiting
2
36
 
Kalytera Therapeutics Israel Ltd, Kalytera Therapeutics Israel Ltd.
Acute Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
 
 
2011-001534-42: Clinical study in which are enrolled patients with malignant hematologic diseases for which there is no indication for allogeneic bone marrow transplantation, and for whom a suitable donor has been identified (fully compatible or partially compatible). Studio clinico nel quale vengono arruolati pazienti affetti da malattie ematologiche maligne, per i quali ci sia indicazione a trapianto di midollo osseo allogenico, e per i quali sia stato individuato un donatore idoneo (totalmente compatibile o parzialmente compatibile).

Ongoing
2
154
Europe
Powder for solution for infusion, Solution for infusion, Tablet, Coated tablet, FLUDARA*EV 5FL 50MG, OVASTAT, ATG FRESENIUS S, MABTHERA*EV 1FL 50ML 500MG, RAPAMUNE*30CPR RIV 2MG, MYFORTIC*250CPR RIV 360MG
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, MEDAC, FRESENIUS BIOTECH
Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched family is from the register. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da patologie maligne ematologiche (leucemia, mieloma, linfoma), candidati a trapianto allogenico da donatore HLA-identico o HLA- mismatched sia familiare che da registro., Pediatric and adult patients (aged 1 to 70 years) suffering from blood cancer (leukemia, lymphoma, etc..) to be undergoing bone marrow transplantation. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da tumori del sangue (leucemie, linfomi etc.) che dovranno essere sottoposti a trapianto di midollo osseo., Diseases [C] - Immune System Diseases [C20]
 
 
2007-005477-54: Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies Condizionamento a base di Treosulfano e profilassi della GvHD con Rapamicina, nel trapianto allogenico non manipolato da donatori alternativi per la cura di patologie neoplastiche ematologiche.

Ongoing
2
85
Europe
FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S, FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S
OSPEDALE S. RAFFAELE DI MILANO
neoplastic and haematologic patologies patologie neoplastiche ed ematologiche
 
 
NCT03357159: Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation

Recruiting
2
30
RoW
Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG)
Sheba Medical Center
Graft Versus Host Disease
12/24
12/24
NCT04530487: Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Terminated
2
1
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Thiotepa, 1,1'',1''''-Phosphinothioylidynetrisaziridine, Girostan, N,N'', N''''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312
M.D. Anderson Cancer Center
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
08/24
08/24
NCT04965597: Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Recruiting
2
40
US
Treosulfan, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon, Trecondi, Fludarabine Phosphate, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl), Beneflur, Fludara, Fludarabine-5'-Monophosphate, SH T 586, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Farmitrexat, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metotrexato, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Antithymocyte globulin rabbit ATG, Imtix, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Quality-of-Life Assessment, Quality of Life Assessment, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, MUGA Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Computed Tomography, Computed Axial Tomography, CAT Scan, CT Scan
Fred Hutchinson Cancer Center, Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, National Heart, Lung, and Blood Institute (NHLBI)
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
12/25
12/26
NCT04083183: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Suspended
1/2
40
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10, Astatine At 211 MAb BC8-B10, At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Fludarabine, 2-Fluorovidarabine, 21679-14-1, 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 21679-14-1, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclostin, Cyclostine, Cytoxan, WR-138719, Lapine T-Lymphocyte Immune Globulin, Anti-thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, Mycophenolate Mofetil, Cellcept, MMF, 115007-34-6, Sirolimus, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Bone Marrow Aspiration, Biospecimen Collection
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Non-Malignant Neoplasm
01/28
01/28
NCT04776850: Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn
1
40
NA
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Mycophenolate Mofetil, CellCept, MMF, Plasmapheresis, Plasma Exchange, Therapeutic Plasma Exchange, Therapeutic Plasmapheresis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center
Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
12/22
12/22
ChiCTR-OND-16009502: Observational study of different dosages of ATG-F used in conditioning of HLA haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion

Recruiting
N/A
40
 
ATG-F 5mg/kg*2d ;ATG-F 5mg/kg*4d
The Second Affiliated Hospital of Chongqing Medical University; the Second Affiliated Hospital, Chongqing Medical University, Provide their own
hematologic malignancy
 
 
Xpovio (selinexor) / Karyopharm
ChiCTR2200056014: Multicentric, open and exploratory clinical study of selinexor combined with pomalidomide and dexamethasone in patients with multiple myeloma

Recruiting
4
10
 
Selinexor combined with Pomalidomide and dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, no
Bozzolo's disease
 
 
ChiCTR2200058238: Multicenter real-world study of selinexor combined with DVd regimen in high-risk relapsed and refractory myeloma

Not yet recruiting
4
35
 
Celinisol + CD38 McAb + bortezomib + dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan
relapsed and refractory myeloma
 
 
ChiCTR2200062860: A single-arm, open, observational clinical study of selinexor combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed patients with extramedullary, plasma cell leukemia, or high-risk multiple myeloma

Recruiting
4
40
 
Selinexor+bortezomib+lenalidomide + dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, none
multiple myeloma
 
 
NCT05786989: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Recruiting
4
32
RoW
selinexor, Selective Inhibitor of Nuclear, KPT-330
Chongqing University Cancer Hospital
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
03/24
09/24
ChiCTR2300069941: Selinexor combined with SC-EPOCH-R in the treatment of newly diagnosed HIV-related diffuse large B-cell lymphoma: a prospective, single-arm, single-center study

Recruiting
4
10
 
selinexor+SC-EPOCH-R
CHONGQING UNIVERSITY CANCER HOSPITAL; CHONGQING UNIVERSITY CANCER HOSPITAL, raise independently
Diffuse large B-cell lymphoma
 
 
ChiCTR2200058237: A multicenter, real-world study of selinexor and VRD regimen in the treatment of newly diagnosed high-risk multiple myeloma

Not yet recruiting
4
35
 
Celinisol + bortezomib + lenalidomide + dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan
Multiple Myeloma
 
 
ChiCTR2300071651: Exploratory study on Selinexor combined with chemotherapy in the treatment of relapsed refractory AML

Recruiting
4
30
 
Selinexor combined with chemotherapy (HMA, HMA-HAG, FLAG)
Zhangzhou Municipal Hospital Affiliated to Fujian Medical University; Zhangzhou Municipal Hospital Affiliated to Fujian Medical University, None
AML
 
 
ChiCTR2300071139: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Not yet recruiting
4
32
 
selinexor combined with R-GemOx
Fuling Hospital Affiliated to Chongqing University; Fuling Hospital Affiliated to Chongqing University, Quzhou City Qujiang District Life Oasis Public Welfare Service Center
diffuse large b-cell lymphoma
 
 
ChiCTR2300075691: Efficacy and safety of selinexor, carfilzomib, pomalidomide, and dexamethasone in the treatment of multiple myeloma with extramedullary disease: a prospective, multicenter, single-arm clinical study

Not yet recruiting
4
55
 
selinexor, carfilzomib, pomalidomide, and dexamethasone
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, self-raised funds
Multiple Myeloma
 
 
ChiCTR2300077623: Clinical study of chemotherapy-free or low-dose chemotherapy regimen containing Selinexor in the treatment of relapsed/refractory acute myeloid leukemia

Recruiting
4
68
 
Selinexor-containing Chemotherapy-free or Low-dose Chemotherapy Regimens
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self financed
Relapsed/Refractory Acute Myeloid Leukemia
 
 
ChiCTR2300077634: Clinical study of selinexor-containing regimens in post-transplant AML patients who molecular relapse but failed after first-line preemptive treatment

Recruiting
4
68
 
Selinexor-containing Chemotherapy-free or Low-dose Chemotherapy Regimens
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-financed
Acute Myeloid Leukemia
 
 
ChiCTR2400086849: A Single-Center, Open-Label, Single-Arm Clinical Study Evaluating the Efficacy and Safety of Selinexor Combined with Melphalan as Preconditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Not yet recruiting
4
42
 
Selinexor plus melphalan
Meishan City Peoples Hospital; Meishan City Peoples Hospital, self-funded sources
Multiple meyloma
 
 
ACTRN12620000291987p: An ALLG Trial to compare the use of Selinexor, Lenalidomide and Dexamethasone with Lenalidomide alone for patients with newly diagnosed Multiple Myeloma undergoing Autologous stem cell transplant.

Not yet recruiting
3
232
 
Australian Leukeamia and Lymphoma Group (ALLG), Karyopharm Therapeutics, Inc
Multiple Myeloma
 
 
ACTRN12620000291987: An ALLG Trial to compare the use of Selinexor with Lenalidomide and Lenalidomide alone for patients with newly diagnosed Multiple Myeloma undergoing Autologous stem cell transplant.

Recruiting
3
232
 
Australian Leukeamia and Lymphoma Group (ALLG), Karyopharm Therapeutics, Inc
Multiple Myeloma
 
 
BOSTON, NCT03110562 / 2016-003957-14: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Calendar Jan 2025 - Dec 2025: Market entry for solid tumors
Checkmark From BOSTON trial for multiple myeloma
Jun 2021 - Jun 2021: From BOSTON trial for multiple myeloma
Checkmark Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
More
Completed
3
402
Europe, Canada, US, RoW
Selinexor, Bortezomib, Velcade®, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
02/20
05/22
ACTRN12620000841976: C-SMART. COVID-19 Prevention and Treatment in Cancer. Arm 3: treatment among cancer patients with moderate COVID-19 infection.

Completed
3
126
 
Peter MacCallum Cancer Centre , Australian Government. Medical Research Future Fund
COVID-19, Cancer
 
 
C-SMART, NCT04534725: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Completed
3
441
RoW
Interferon alfa, Selinexor, Lenzilumab
Peter MacCallum Cancer Centre, Australia
Cancer, Covid19, Respiratory Viral Infection
11/22
04/23
2022-002540-42: A MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH ENDOMETRIAL CARCINOMA ENSAYO MULTICÉNTRICO DE SELINEXOR COMO TERAPIA DE MANTENIMIENTO PARA PACIENTES CON CÁNCER DE ENDOMETRIO

Not yet recruiting
3
220
Europe
Selinexor, KPT-330, Coated tablet, NEXPOVIO
Karyopharm Therapeutics Inc., KARYOPHARM THERAPEUTICS, INC., Karyopharm Therapeutics Inc.
Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with p53 wild-type, advanced or recurrent endometrial cancer Selinexor/placebo se administrará como terapia de mantenimiento después de la quimioterapia combinada para pacientes con cáncer de endometrio avanzado o recurrente de tipo p53 salvaje, Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with endometrial cancer Selinexor/placebo se administrará como terapia de mantenimiento después de la quimioterapia combinada para pacientes con cáncer de endometrio, Diseases [C] - Cancer [C04]
 
 
NCT06158841: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Japan, US, RoW
ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
07/24
10/24
NCT06613035: Twice-per-weekSelinexor, 2 Days Melphalan

Not yet recruiting
3
126
RoW
Selinexor, Melphalan, Intravenous Busulfan, Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
09/27
09/27
SIENDO, NCT03555422 / 2017-000607-25: Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer []

Hourglass Sep 2023 - Oct 2023 : Presentation of data from SIENDO trial for TP53 wild-type endometrial cancer at ESGO 2023
Checkmark Subgroup analysis data from SIENDO trial for TP53 wild type endometrial cancer
Jan 2023 - Jan 2023: Subgroup analysis data from SIENDO trial for TP53 wild type endometrial cancer
Checkmark Data from SIENDO study in endometrial cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from SIENDO study in endometrial cancer at ASCO 2022
More
Active, not recruiting
3
263
Europe, Canada, US, RoW
Selinexor, Matching placebo for selinexor
Karyopharm Therapeutics Inc, Belgium and Luxembourg Gynaecological Oncology Group, North-Eastern German Society of Gynaecologic Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, GOG Foundation
Endometrial Cancer
01/22
12/25
NCT05726110: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
3
50
RoW
Selinexor, KPT-330, Homoharringtonine, HHT, Daunorubicin, DNR, Cytarabine, Ara-C, Granulocyte Colony-Stimulating Factor, G-CSF, Aclacinomycin, ACM
Shanxi Bethune Hospital, Antengene Corporation
Relapsed or Refractory Acute Myeloid Leukemia
12/24
12/24
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
2011-000749-19: AML LI1

Ongoing
2/3
800
Europe
AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid
Cardiff University
Acute myeloid leukemia and high-risk myelodysplastic syndrome
 
 
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT05822050: An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Recruiting
2/3
20
RoW
Selinexor
The First Hospital of Jilin University
PTCL Patients Who Achieved Complete Response From Frontline Treatment
12/24
06/25
ACTRN12621001361897p: A single arm, open-label study of Exportin 1 inhibitor selinexor in relapsed/refractory central nervous system (CNS) Lymphoma and in relapsed/refractory CNS Myeloma

Not yet recruiting
2
20
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Central nervous system diffuse large B cell lymphoma; Central nervous system myeloma
 
 
ACTRN12621001361897: A single arm, open-label study of Exportin 1 inhibitor selinexor in relapsed/refractory central nervous system (CNS) Lymphoma and in relapsed/refractory CNS Myeloma

Not yet recruiting
2
20
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Central nervous system diffuse large B cell lymphoma, Central nervous system myeloma
 
 
ACTRN12622001366741: Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial

Recruiting
2
120
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Multiple Myeloma
 
 
ACTRN12622001313729: ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd)

Recruiting
2
140
 
Australasian Leukaemia & Lymphoma Group, Australasian Leukaemia & Lymphoma Group
Relapsed/ Refractory Multiple Myeloma
 
 
2014-002444-40: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma. Inductie en consolidatie behandeling met selinexor gecombineerd met bortezomib en dexamethason voor patiënten met Multipel Myeloom met verslechtering van het ziektebeeld.

Ongoing
2
37
Europe
bortezomib, selinexor (20 mg), selinexor (10mg), KPT-330, Velcade, Velcade
Erasmus MC, karyopharm
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma. Inductie en consolidatie behandeling met selinexor gecombineerd met bortezomib en dexamethason voor patiënten met Multipel Myeloom met verslechtering van het ziektebeeld.
 
 
2014-001876-75: Study for patients with leukemic cells in their bone marrow

Ongoing
2
230
Europe
selinexor (20 mg), KPT-330, Tablet
HOVON Foundation, HOVON Foundation, Karyopharm Therapeutics
patients ≥ 66 years with: - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or - acute leukemia's of ambiguous lineage according to WHO 2008 or - a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R > 4.5, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04]
 
 
2017-001736-19: Selinexor, cyclophosphamide and prednisolone compared to cyclophosphamide and prednisolone in patients with multiple myeloma

Not yet recruiting
2
60
Europe
Selinexor, Cyclophosphamide, Prednisolone, Tablet, Cyclophosphamide, Prednisone
University of Leeds
Multiple myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2017-002326-21: Clinical Trial with selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma Ensayo clínico de selinexor (KPT-330), bortezomib y dosis baja de dexametasona más daratumumab (SELIBORDARA) para el tratamiento de pacientes con mieloma múltiple en recaída y/o refractario

Ongoing
2
62
Europe
DARZALEX, VELCADE, Selinexor, Infusion, Solution for injection, Tablet, DARZALEX, VELCADE
Fundación PETHEMA, Fundación Pethema
Patients with refractory or relapsed and refractory multiple myeloma Pacientes con mieloma múltiple en recaída y/o refractario, patients with multiple myeloma Pacientes con mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
MUKtwelve, NCT06212596: Selinexor, Cyclophosphamide and Prednisone in Myeloma

Completed
2
66
Europe
Selinexor, Cyclophosphamide, Prednisone
University of Leeds
Relapsed or Refractory Multiple Myeloma
10/22
11/23
2020-006060-89: Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe)

Not yet recruiting
2
50
Europe
Selinexor, Revlimid, Bortezomib, Dexamethasone, Tablet, Capsule, hard, Injection, Selinexor, Revlimid, Bortezomib, Dexamethasone
Odense University Hospital, Nordic Myeloma Study Group
Multiple myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2021-006229-23: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. Studio pilota di fase II di Selinexor in combinazione con Ifosfamide, Etoposide e Desametasone (SIDE) in pazienti con linfoma a cellule T periferiche recidivato o refrattario.

Not yet recruiting
2
30
Europe
HOLOXAN, Selinexor, Decadron, Etoposide, [HOLOXAN], [Selinexor], [Decadron], [Etoposide], Powder for solution for injection/infusion, Tablet, Solution for injection, Concentrate for solution for injection/infusion, HOLOXAN - 1 G POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, DECADRON - 8 MG/2 ML SOLUZIONE INIETTABILE 3 FIALE DA 2 ML, ETOPOSIDE TEVA - 1 FLACONE 5 ML 20MG/ML
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, Diseases [C] - Cancer [C04]
 
 
GEM-SELIBORDARA, NCT03589222: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Recruiting
2
62
Europe
Selinexor, Daratumumab, Bortezomib, Dexamethasone
PETHEMA Foundation
Refractory Multiple Myeloma
08/23
08/23
SPODUMENE, NCT05478993: Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

Recruiting
2
21
RoW
SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
Peking University People's Hospital, Qingdao Municipal Hospital
Multiple Myeloma
07/24
07/25
NCT04768881: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Terminated
2
15
US
Selinexor, KPT-330, XPOVIO®, Pembrolizumab, KEYTRUDA®
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
09/23
09/23
SEARCH, NCT03992339: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Active, not recruiting
2
60
RoW
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle, Selinexor
Antengene Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
12/23
06/24
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
NCT05974085: XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Recruiting
2
10
RoW
Selinexor+RCHOP
Zhejiang Cancer Hospital
Double Hit Lymphoma, Triple Hit Lymphoma
12/23
03/24
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
PORCH, NCT04998760: A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( )

Not yet recruiting
2
96
RoW
ATG-008, ATG-010
Qi Zhou
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
01/24
04/24
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
2
20
RoW
Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/24
02/24
ESSENTIAL, NCT03627403: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Checkmark Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Nov 2022 - Nov 2022: Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Checkmark New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Nov 2021 - Nov 2021: New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Checkmark Data from ESSENTIAL trial for myelofibrosis
More
Active, not recruiting
2
17
US
Selinexor
University of Utah, Karyopharm Therapeutics Inc
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
08/23
03/25
NCT06062641: Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Not yet recruiting
2
50
RoW
SR-GDP
Ruijin Hospital
Relapsed or Refractory B-cell Lymphoma
04/24
09/27
NCT02835222: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Checkmark Data from trial for older patients with acute myeloid leukemia at ASH 2020
Dec 2020 - Dec 2020: Data from trial for older patients with acute myeloid leukemia at ASH 2020
Recruiting
2
100
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Untreated Adult Acute Myeloid Leukemia
06/25
06/25
SABLe, NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting
2
50
Europe
Selinexor 20 MG Oral Tablet, Xpovio, Bortezomib Injection, Velcade, Lenalidomide capsule, Revlimid, Dexamethasone Oral, Neofordex
Ida Bruun Kristensen, Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Multiple Myeloma
06/24
06/29
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Recruiting
2
141
Europe, RoW
Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
06/24
06/25
NCT06517511: Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Recruiting
2
42
RoW
Selinexor Oral Tablet [Xpovio], exportin 1 (XPO1) inhibitor, R-CHOP Protocol, R-CHOP regimen
Sun Yat-sen University, Fudan University
Diffuse Large B Cell Lymphoma
01/26
04/28
NCT06169215: Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Recruiting
2
70
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ 54767414, JNJ-54767414, JNJ54767414, Daratumumab and Recombinant Human Hyaluronidase, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab and Hyaluronidase, Daratumumab and Hyaluronidase-fihj, Daratumumab and vorhyaluronidase, Daratumumab and Vorhyaluronidase Alfa, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, Darzquro, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Multiple Myeloma
09/26
09/26
NCT05900882: SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Recruiting
2
35
RoW
Selinexor, S, Bortezomib, V, Lenalidomide, R, Dexamethasone, d
The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
08/24
06/25
NCT05951855: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Recruiting
2
42
RoW
Selinexor, X, Chidamide, C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (Relapsed/Refractory)
09/24
03/25
NCT06573138: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Not yet recruiting
2
18
NA
Selinexor, anti-PD-1 antibody plus Golidocitinib
Ruijin Hospital
Lymphoma, Extranodal NK-T-Cell
07/27
07/27
RJ-NKTCL-5, NCT06573151: Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Not yet recruiting
2
28
NA
Selinexor, anti-PD-1 antibody and P-GemOx
Ruijin Hospital
Lymphoma
07/27
07/27
NCT04756401: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Active, not recruiting
2
52
US
Carfilzomib, Kyprolis, PR-171, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Quality-of-Life Assessment, Quality of Life Assessment, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/24
12/27
ChiCTR2200064695: A phase II trial of selinexor, pomadomide, bortezomib combined with dexamethasone in newly diagnosed multiple myeloma with renal insufficiency

Not yet recruiting
2
62
 
Selinexor, pomadomide, bortezomib combined with dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Clinical Research Incubation Project in 2022
Multiple myeloma
 
 
ChiCTR2200057942: Clinical study of selinexor combined with CHOP regimen with or without ASCT followed by selinexor monotherapy maintenance therapy in patients with newly diagnosed peripheral T-cell lymphoma

Not yet recruiting
2
32
 
selinexor + CHOP
Jiangsu Province Hospital; Jiangsu Provincial People's Hospital, Antengene Corporation
PTCL
 
 
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
18
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
08/24
11/25
NCT06652139: Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

Not yet recruiting
2
82
NA
selinexor combined with BEAM regimen, SINE+BEAM, BEAM regimen, BEAM
Ruijin Hospital
Diffuse Large B Cell Lymphoma
11/26
11/28
NCT06664970: A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Enrolling by invitation
2
39
RoW
Azacitidine or Ruxolitinib combined with Selinexor
Peking Union Medical College Hospital
MDS
09/25
09/26
LAUNCH, NCT04877275: ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Recruiting
2
50
RoW
Selinexor (80mg/d), ATG-010, Selinexor (100mg/d), Pegylated liposomal doxorubicin, PLD, Dexamethasone, Dex, Cyclophosphamide, CTX
Chunyan Sun, MD
Multiple Myeloma
12/24
12/24
NCT05597345: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Recruiting
2
15
US
Selinexor
University of Rochester, Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
12/24
12/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
AVS, NCT05736978: Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

Recruiting
2
58
RoW
Azacitidine, Venetoclax, ABT-199, Selinexor, XPO1 inhibitor
Shanghai Tong Ren Hospital
AML, MRD
03/25
03/27
SAV, NCT05736965: A Study of Selinexor in Combination With Azacitidine and Venetoclax ( Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Recruiting
2
58
RoW
Selinexor, xpo1 inhibitor, Azacitidine, Venetoclax, ABT199
Shanghai Tong Ren Hospital
AML, Adult
03/25
04/27
CAC-MM-001, NCT05850286: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based Regimen
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
04/25
04/27
NCT05870917: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, Bortezomib, Lenalidomide and Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Leukemia
04/25
04/27
NCT05333458: Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Recruiting
2
77
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
05/25
05/25
 

Download Options